Oxygen therapy – Page 2 – Communicable Diseases Research

Dual effects of supplemental oxygen on pulmonary infection, inflammatory lung injury, and neuromodulation in aging and COVID-19

Review article

Published on 2022-09-012022-10-05
Journal: Free radical biology & medicine
[Category] SARS, 바이오마커, 유전자 메커니즘,

Covid-19, an unfinished story

Mini review

Published on 2022-09-012022-10-05
Journal: La Presse Médicale
[Category] COVID19(2023년), SARS, 변종, 치료제,

[키워드] activities acute respiratory distress age amplitude bat coronavirus Beta Betacoronavirus caused China Cluster Comorbidities compulsory vaccination condition confirmed case coronavirus COVID-19 Critical cross deaths degree Delta detect development drug effective Efficacy epidemic waves epidemiological surveillance evade Face mask FIVE form Gamma Genome genomic Health highly pathogenic homogeneity Host Human immune response Immunity incidence rate include Inflammatory Innovation intensive care Measures Messenger RNA mild infection Moderna mRNA vaccine multiorgan failure nucleotides occupancy rate omicron Oxygen therapy pandemic Patient Pfizer-BioNTech Pneumonia preventing the transmission progressed Protective replaced RNA SARS-CoV-2 SARS-CoV-2 vaccine Sequencing severity syndrome the WHO thromboembolic complications Vaccine Vaccines variant variants variants of concern viral invasion VoC WHO World Health Organization
[DOI] 10.1016/j.lpm.2022.104131 [Article Type] Mini review

Clinical efficacy of casirivimab-imdevimab antibody combination treatment in patients with COVID-19 Delta variant

코로나19 델타 변이형 환자에서 카시리비맙-임데비맙 항체 병용요법의 임상적 효능

Article

Published on 2022-09-012022-09-11
Journal: Journal of infection and chemotherapy : official j
[Category] COVID19(2023년), SARS, 변종, 임상, 진단, 치료법,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus 2 administration age antibody cocktail antibody combination antibody treatment Casirivimab Casirivimab-imdevimab treatment clinical Clinical efficacy cocktail Combination conducted control group coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient death Delta delta variant dose Efficacy evaluate FIVE High flow nasal cannula high-risk patient High-risk patients hospital Hospitalization Imdevimab inclusion criteria intravenously Japan mechanical ventilation monoclonal antibodies monoclonal antibody nasal nasal cannula Neutralizing antibodies outcome oxygen Oxygen therapy Patient patients with COVID-19 receive reduce reduced respiratory risk SARS-CoV-2 SARS-CoV-2. significantly lower therapy Treatment treatment group Viral Viral load with COVID-19
[DOI] 10.1016/j.jiac.2022.05.012 PMC 바로가기 [Article Type] Article

Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong’s omicron BA.2 wave: a retrospective cohort study

Research article

Published on 2022-08-242022-10-05
Journal: The Lancet. Infectious Diseases
[Category] COVID19(2023년), SARS, 변종, 신약개발, 치료제,

[키워드] 1:1 Abstract Admission all-cause mortality analysed Antiviral Antiviral treatment authority calculated Chinese clinical benefit contraindication Control controls COVID-19 COVID-19 diagnosis Cox regression models Cycle threshold value Department diagnosis of SARS-CoV-2 Disease progression Effectiveness eligible evaluate event exclusion finding Follow-up for inclusion funding hazard ratio Hong Kong hospital hospitalised hospitalised patient HRs ICU admission IMV incidence rate Infection intensive care Invasive mechanical ventilation lower risk material Mild-to-moderate molnupiravir need for oxygen oral outcome outcomes Oxygen therapy pandemic Patient patients Primary outcome recipient Region registry renal required retrospective cohort retrospective cohort study RT-PCR SARS-CoV-2 SARS-COV-2 infection secondary outcome severe liver impairment Significant significantly shorter study period supplemental oxygen Support symptom onset therapy time translation viral burden virological outcome were excluded with COVID-19
[DOI] 10.1016/S1473-3099(22)00507-2 [Article Type] Research article

Breakthrough COVID-19 Infection During the Delta Variant Dominant Period: Individualized Care Based on Vaccination Status Is Needed

Article

Published on 2022-08-152022-11-16
Journal: Journal of Korean medical science
[Category] SARS, 변종,

Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial

Randomized Controlled Trial

Published on 2022-08-042022-10-04
Journal: The European Respiratory Journal
[Category] Fulltext, SARS, 임상,

[키워드] 1:1 28-day mortality 95% CI age assigned Clinical improvement clinical status clinical trial Controlled trial coronavirus disease COVID-19 death demonstrated Dexamethasone discharged Effect Efficacy enrolled Evidence High dose High-dose high-dose group hospitalised hospitalised COVID-19 patient hospitalised patient low dose low-dose male moderate no significant difference Open-label outcome oxygen Oxygen therapy Patient performed Pneumonia Primary outcome randomisation randomised Randomly receive reduced secondary seven-point ordinal scale severe COVID-19 Time to recovery worsening
[DOI] 10.1183/13993003.02518-2021 PMC 바로가기 [Article Type] Randomized Controlled Trial

Therapeutic anticoagulation using heparin in early phase severe coronavirus disease 2019: A retrospective study

Observational Study

Published on 2022-08-012022-10-05
Journal: The American journal of emergency medicine
[Category] 임상,

[키워드] administration adverse event Anticoagulant anticoagulation association Care Characteristics Coronavirus disease 2019 COVID-19 Critical care disease early administration early phase ECMO Effect extracorporeal membrane oxygenation group groups heparin hospital ICU in-hospital mortality in-hospital mortality rate intensive care intensive care unit Japan mechanical ventilation multivariate model outcome Oxygen therapy Patient Pneumonia retrospective Retrospective study secondary outcome severe coronavirus disease severe COVID-19 patient Severe COVID-19 pneumonia significantly significantly lower systemic anticoagulation therapeutic therapeutic anticoagulation Therapeutic anticoagulation. therapy unfractionated heparin ventilator-free day VFD
[DOI] 10.1016/j.ajem.2022.05.031 PMC 바로가기 [Article Type] Observational Study

Association of triglyceride-glucose index with prognosis of COVID-19: A population-based study

COVID-19의 예후와 트리글리세리드-글루코스 지수의 연관성: 인구 기반 연구

Article

Published on 2022-08-012022-09-11
Journal: Journal of infection and public health
[Category] MERS, 바이오마커, 진단,

[키워드] 95% confidence interval adjusted adjusted odds ratio calculated Care Chain Reaction complications of COVID-19 Composite COVID-19 COVID-19 cohort COVID-19 infected patients COVID-19 infection COVID-19 patient COVID-19 patients dataset defined diagnosed diagnosis of COVID-19 Diseases evaluated fasting glucose Glucose Health health screening high-flow oxygen therapy increased risk infected patients Infection Infectious diseases insulin insulin resistance intensive care marker Mean ± standard deviation mechanical ventilation Mortality multivariate logistic regression outcome oxygen Oxygen therapy patients patients with COVID-19 polymerase chain polymerase chain reaction Primary outcome Prognosis Prognostic value reverse transcription reverse transcription polymerase chain reaction risk factor severe complication severe complications severity of COVID-19 shown Standard deviation Triglyceride Triglyceride-glucose index.
[DOI] 10.1016/j.jiph.2022.06.014 PMC 바로가기 [Article Type] Article

The association of airborne particulate matter and benzo[a]pyrene with the clinical course of COVID-19 in patients hospitalized in Poland

Research article

Published on 2022-08-012022-10-05
Journal: Environmental pollution (Barking, Essex : 1987)
[Category] 바이오마커, 변종,

Evaluation of Remdesivir for Mildly to Moderately Ill Patients with COVID-19: A Single-Arm, Single-Center, Retrospective Study

경증에서 중등도의 COVID-19 환자를 위한 렘데시비르 평가: 단일 암, 단일 센터, 후향적 연구

Article

Published on 2022-07-272022-09-11
Journal: Medicina
[Category] COVID19(2023년), SARS, 치료기술,

[키워드] 6-point ordinal scale Adverse adverse events Alanine alanine aminotransferase Antiviral antiviral agent approved Clinical improvement clinical status Common Terminology Criteria coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient CTCAE death discharge effective Efficacy and safety elevated enrolled event grade 3 hospital Ill ill patient initiated Japan Japanese material neutropenia objective one patient Ordinal Scale oxygen Oxygen therapy Patient patients patients with COVID-19 primary end point profiles RDV receiving Remdesivir remdesivir. required Result Retrospective study single-center study period Treatment university was performed were assessed with COVID-19
[DOI] 10.3390/medicina58081007 PMC 바로가기 [Article Type] Article